Getinge AB Class B

Getinge AB Class B

27.91
USD
+0.01
(+0.04%)
1.05EPS
23.65P/E
6.69BMarket Cap
Jan 26Next Earn
Getinge AB Class B
OTC:GNGBY
(OTC Markets)

Recent

price

27.91

P/E

ratio

23.65

div

yld

1.73%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
88.15
86.89
96.41
100.54
106.03
120.21
92.16
90.17
89.19
98
110.03
99.81
104.39
117.44
128.26
129.03
127.14
Revenue per Share
9.05
10.06
10.02
9.09
5.7
5.53
4.94
5.52
-3.57
4.51
11.95
10.96
9.19
8.9
6.04
8.33
10.44
Basic EPS, GAAP
11.38
8.89
7.88
7.4
10.25
6.8
9.34
4.41
9.24
9.64
22.71
20.77
8.23
5.92
12.06
9.72
15.94
Free Cash Flow per Basic Share
2.6
3.08
3.55
3.93
3.95
2.75
2.85
1.98
1.56
1.1
1.6
3.17
4.1
4.36
4.53
4.68
4.83
Dividend per Share
55.76
58.08
60.31
65.73
72.93
76.35
81.54
71.53
70.85
75.63
77.58
91.32
110.84
111.31
121.79
108.59
120.48
Book Value per Share
-25.3
-39.32
-38.67
-34.18
-46.61
-45.09
-45.71
-13.51
-18.07
-13.97
-3.92
2.22
11.17
-1.86
-23.01
-15.07
-13.74
Tangible Book Value per Share
252
252
252
252
252
252
241
249
271
271
271
271
271
271
271
271
271
Basic Weighted Avg Shares
22,172
21,854
24,248
25,287
26,669
30,235
22,170
22,495
24,172
26,559
29,819
27,049
28,291
31,827
34,759
34,968
34,456
Sales/Revenue/Turnover
17.45
18.76
17.46
16.46
14.42
11.31
12.08
10.03
-1.17
10.19
16.87
16.07
13.7
11.61
10.63
12.77
13.58
Operating Margin (%)
- -
- -
- -
- -
- -
- -
2,703
2,609
1,808
2,223
2,467
1,814
2,027
2,093
2,422
2,250
2,173
Depreciation Expense
2,277
2,529
2,521
2,285
1,433
1,390
1,188
1,376
-967
1,222
3,239
2,970
2,491
2,412
1,638
2,258
2,829
Net Income, GAAP
26.83
26.34
26.34
27.21
27.13
27.04
26.15
- -
- -
34.21
27.05
28.34
27.53
27.37
27.52
27.63
27.35
Effective Tax Rate (%)
10.27
11.57
10.4
9.04
5.37
4.6
5.36
6.12
-4
4.6
10.86
10.98
8.8
7.58
4.71
6.46
8.21
Profit Margin (%)
4,935
5,241
3,070
4,029
1,630
3,880
3,896
2,292
4,143
4,630
7,643
4,459
7,113
3,462
3,115
4,185
3,343
Working Capital
11,411
15,121
13,163
13,566
14,378
16,006
15,914
4,962
7,378
7,068
7,687
3,495
5,031
4,960
8,280
8,922
8,022
LT Debt
13,248
14,636
15,200
16,560
18,694
19,593
20,916
19,806
19,655
20,973
21,486
25,176
30,453
30,403
33,210
29,493
32,710
Total Equity
9.84
10.08
9.19
8.21
5.28
4.98
2.68
- -
- -
5.07
11.1
10.17
7.94
7.23
5
6.45
7.72
Return on Invested Capital (%)
9.8
9.99
9.09
8.12
5.17
4.6
3.68
- -
- -
4.75
10.81
9.96
7.95
7.32
5
6.45
6.71
Return on Capital (%)
17.57
18.17
16.93
14.42
8.22
7.4
5.98
6.9
-5.01
6.16
15.6
12.98
9.09
8.01
5.19
7.23
9.2
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,987
2,011
3,210
LT Borrowings
7,953
7,942
6,811
LT Finance Leases
1,048
1,147
1,211
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
271
271
271
Market Capitalization
50,903
53,416
66,911

Working Capital

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
17,437
15,769
16,987
Cash, Cash Equivalents & STI
4,020
2,052
3,157
Accounts Receivable, Net
4,931
5,087
4,837
Inventories
6,578
6,840
7,191
Total Current Liabilities
12,927
12,034
13,644
Payables & Accruals
- -
- -
- -
ST Debt
1,987
2,011
3,210
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.59%
7.2%
-11.19%
Free Cash Flow
23.52%
-2.52%
-19.37%
Net Income, GAAP
-25.21%
-4.37%
37.85%
Sales/Revenue/Turnover
2.2%
3.52%
0.6%
Total Cash Common Dividend
11.37%
28.22%
3.26%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,513
8,305
7,870
11,071
34,759
2025
8,320
8,238
- -
10,186
34,968
2026
7,443
8,381
8,446
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.69
1.89
0.01
2.45
6.04
2025
1.11
1.93
- -
3.2
8.33
2026
1.48
3.1
2.65
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
4.46
0.02
0.04
4.53
2025
- -
4.65
- -
0.01
4.68
2026
- -
4.82
- -
- -
- -
Business
Getinge AB (publ) Getinge AB (publ) develops, manufactures and markets medical equipment, systems and services for operating rooms, intensive care units, sterilization departments, cardiovascular procedures and life science applications to healthcare providers and life science institutions worldwide. The company operates through three main business areas including Acute Care Therapies, which provides life support solutions for critical conditions such as heart-lung machines, ventilators and monitoring systems; Surgical Workflows, which supplies operating tables, lights, sterile reprocessing equipment including washers, disinfectors and sterilizers, along with advanced IT systems for hospital efficiency and fluorescence imaging tools; and Life Science, which offers contamination control equipment, single-use solutions and biopharmaceutical production systems. Getinge AB (publ) sells its products in more than 135 countries and employs approximately 12,000 people. Founded in 1904 and headquartered in Gothenburg, Sweden, the company continues to expand through strategic acquisitions such as Paragonix Technologies in 2024 to bolster organ transplantation capabilities, Healthmark Industries, HPNE and Ultra Clean Systems in 2023 to strengthen sterile reprocessing and life science offerings, alongside a partnership with Zimmer Biomet announced in 2025 to support orthopedic procedures; it also reported record growth, high customer satisfaction and successful product launches across all areas in its 2024 annual report.

Company News

  • Getinge AB (publ) (GNGBY) Q3 2026 Earnings Call Transcript

  • Getinge AB (publ) (GNGBY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • Getinge AB (publ) (GNGBY) Q2 2026 Earnings Call Transcript

  • Getinge AB (publ) (GNGBY) Q1 2026 Earnings Call Transcript

  • Analyzing Danaher (NYSE:DHR) and Getinge (OTCMKTS:GNGBY)

  • Getinge AB (publ) (GNGBY) Q4 2025 Earnings Call Transcript

  • Contrasting AMN Healthcare Services (NYSE:AMN) & Getinge (OTCMKTS:GNGBY)

  • Reviewing Getinge (OTCMKTS:GNGBY) & Pediatrix Medical Group (NYSE:MD)

  • Getinge AB (publ) (GNGBY) Q3 2025 Earnings Call Transcript

  • Getinge AB (publ) (GNGBF) Q2 2025 Earnings Call Transcript

  • Getinge AB (publ) (GNGBF) Q1 2025 Earnings Call Transcript

  • Getinge AB (GNGBF) Q4 2024 Earnings Call Transcript

  • Getinge AB (GNGBF) Q3 2024 Earnings Call Transcript

  • Getinge misses Q3 forecasts, weighed by quality and delivery issues

  • Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript

  • Getinge AB (GNGBF) Q1 2024 Earnings Call Transcript

  • Getinge AB (publ) (GNGBF) Q3 2023 Earnings Call Transcript

  • Getinge: Turnaround Catalysts To Outperform Healthcare Peers

  • Getinge AB (publ) (GNGBF) Q2 2023 Earnings Call Transcript

  • Getinge AB (publ) (GNGBF) Q4 2022 Earnings Call Transcript